Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase - Wikidata - awgldk - TriplyDB

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

http://www.wikidata.org/entity/Q27026912

about

Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review Targets for Ibrutinib Beyond B Cell Malignancies Discovery of host-targeted covalent inhibitors of dengue virus The Essential Medicinal Chemistry of Curcumin PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS.Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma in the Elderly: A Matched Case-Control Analysis.The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement How to unleash mitochondrial apoptotic blockades to kill cancers?Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Ibrutinib-A double-edge sword in cancer and autoimmune disorders.Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Venetoclax for the treatment of patients with chronic lymphocytic leukemia.The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.Synthesis of Diverse (11)C-Labeled PET Radiotracers via Direct Incorporation of [(11)C]CO2.Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages.Ibrutinib treatment improves T cell number and function in CLL patients.Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.

P2860

Q27304386-7CFD3BC8-A5FC-4113-B16F-B7DF38250078 Q28087772-C2295F67-4C3B-4CAB-AA5B-7F0A4140F38B Q28733542-25D4F570-D587-4D20-9649-92163507A449 Q30841584-1FB1DFE9-6EA7-464B-AEAE-CF012EC75B97 Q34460371-8ED09934-88D6-455D-BD34-8ABD7D3C6272 Q35723777-16E871BE-B117-4D6B-9AEA-0659FF35043D Q36350848-9136D050-4B20-46EF-89E7-E94E8EC375C4 Q37587294-64892354-FF36-458E-966C-A2685A3C4EEE Q37731677-B64730D8-4438-406D-B4D8-347639E0D7AC Q38554422-527449B4-016A-4F41-AB24-B3B39685A3F8 Q38585329-9D0BF7F3-67F4-4A5C-8D4C-8520E3ECED4E Q38601727-7E029694-4D90-4D9B-BFE3-003421DFAF4E Q38685358-6BF29B24-FB4E-4854-B7C8-895FA2F8A9A2 Q38719429-5EA12AC0-24F3-4CB7-8997-DABD669DD318 Q38889962-484A5B53-6AA5-40C4-9EBA-497462DB78E2 Q39006397-422EC844-09AB-49FA-B788-F8E1A4370780 Q39010883-FC642F01-6822-4CE4-A026-D066FB59E334 Q42011591-A928982F-FBC5-47F0-8B02-9BBD1E70CB70 Q42660684-337B99C6-AFAD-4477-AD9B-B43B7790D58C Q42909982-614CB1CE-0689-4FD5-86F2-5E25D2CF61D6 Q47932240-A8658B71-3586-46A0-93AF-A6B94A254785 Q52686217-60C21A3F-5984-4B93-ADB6-984BF17C3137 Q53963822-8558EB0A-B72E-4B3C-A8B4-3A835FE11310 Q54987383-A1731319-081D-4B09-8C68-37F0F2131EDA

P2860

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

http://www.wikidata.org/entity/Q27026912

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@ast

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@en

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@nl

type

label

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@ast

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@en

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@nl

prefLabel

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@ast

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@en

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@nl

P1433

Q27026912-2DCCBDA5-6862-42F8-AB5F-826FF458716A

P1476

Q27026912-87349B97-A031-42FD-A827-D4D5A76BFD38

P2093

Q27026912-BA4516E7-C9B2-4E05-9560-3B22038B937F

Q27026912-F61F1E0E-7080-48D3-AEA9-B5D450DD3D74

P2860

Q27026912-1224B515-7F94-42CF-A18B-EE0287731E0D

Q27026912-248B5D82-6E6F-4A0B-A6B7-A4BC44C8C148

Q27026912-27561A65-72B8-4DFF-AD56-83815391A720

Q27026912-46F03330-B9D3-476C-977B-8816438D8DA8

Q27026912-607F8F89-B905-4F6E-89AA-1E9E02D0B708

Q27026912-6712F9BB-AA83-473C-9C39-486B8D998A79

Q27026912-75422E12-AA48-44A8-9D0F-57EABA9BF044

Q27026912-82A8F1F6-EBEF-4BD4-BF87-43AA4D38ECFA

Q27026912-83B7F3A7-653E-438E-A6D0-196E39315B10

Q27026912-9D0BB901-0662-4F5B-9348-B3F9A7823C42

P304

Q27026912-46DBF246-92D8-45C9-B319-5CF1C956EE89

P31

Q27026912-F4A31C08-64E4-4777-8DC8-27EE1612C8CC

P356

Q27026912-68022F9D-CEF4-48BD-BB80-B9C290A43B58

P407

Q27026912-F0B4D2C6-2E3E-4C6C-B050-D30B83506EED

P433

Q27026912-EAAE9472-9AB3-454E-8DD1-224BB93B9340

P478

Q27026912-13FC581C-5D25-4B2B-9263-2E38B12BFCAD

P577

Q27026912-FDF9DAE0-5DB5-4587-B6A1-28AB697B6D8C

P698

Q27026912-62E39FEC-252D-4B44-9E44-581D60E72971

P932

Q27026912-0B08A124-CFA7-400C-8DB4-AFE31E67BBCE

P356

P1433

Future Oncology

P1476

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase

@en

P2093

Jennifer R Brown

http://www.w3.org/2001/XMLSchema#string

Matthew S Davids

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

P304

957-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON.14.51

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2014-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24941982

http://www.w3.org/2001/XMLSchema#string

P932

4632638

http://www.w3.org/2001/XMLSchema#string